Baricitinib (Olumiant)
What is Baricitinib?
Baricitinib (Olumiant) is an oral Janus kinase (JAK) inhibitor. In dermatology-related care, it is used to treat adults with severe alopecia areata. It is not typically recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine, or other potent immunosuppressants.
How does Baricitinib work?
Baricitinib works by blocking JAK signaling inside cells. JAK enzymes help transmit inflammatory signals that affect immune-cell function, and blocking these pathways helps reduce immune-driven inflammation involved in conditions such as alopecia areata.
What are possible side effects of Baricitinib?
Common side effects can include:
Upper respiratory infections
Headache
Nausea
More serious risks can include:
Serious infections
Blood clots
Major cardiovascular events
Certain cancers
Because of these risks, providers may review your medical history and monitor bloodwork during treatment.
How is Baricitinib used?
Baricitinib is taken by mouth once daily, with or without food. The specific dose may vary based on the patient and treatment plan. Providers may adjust treatment over time depending on response, side effects, and lab results.
Before starting baricitinib, providers generally review for active or latent tuberculosis, screen for viral hepatitis, and check blood counts plus liver and kidney function. Live vaccines are avoided during treatment, and monitoring during therapy may include blood counts, liver enzymes, and lipids. The prescribing information also states that baricitinib may cause fetal harm based on animal data, and breastfeeding is not recommended during treatment.